Site Calendar
Site Geotagged Content
Site Members
1 - 2 of 2
All Members

 

We combine innovative high throughput technologies (e.g. next generation sequencing,
real-time PCR, microarrays) with our own in-house workflow-based data analysis tools
to support our partners and customers in the ultimate goal of defining biomarkers for
personalized medicine and early disease detection.
 

CANCER & COMPLEX DISEASE DIAGNOSTICS

 

Biomarkers are endogenous molecules specific to certain diseases. They can either be found in the diseased organ or in body fluids such as serum, urine and saliva. Cancer is a disease causing extensive genetic changes which have complex effects on gene regulation, expression and translation. Multivariate analysis of different biomolecules can help us improve the way we diagnose and manage this and other complex age-related diseases. We specialize in genome-wide screenings to elucidate changes in RNA (mRNA, miRNA,...), DNA (structural changes and mutations), DNA methylation and serum autoantibodies. Candidate marker sets are identified using bioinformatic analysis from whole genome microarrays and next generation sequencing (NGS on IonTorrent™ and IonProton™ systems). By designing targeted assays based on customized batch-processing software tools we enable fast and reliable marker validation. We assist clinical and industrial partners in project planning and act as technology providers and developers. Together we set up projects designed to answer disease-relevant questions and meet the challenges of translational research.

 

REFERENCE PROJECTS:

 

1) RESOLVE:

Research:       

- Microarrays for infectious disease- and cancer diagnosis

- Quantitative proteomics

 

The AIT performed gene expression-, DNA methylation- and microRNA
expression analyses on human and mouse model systems using whole
genome microarrays. Further quantitative proteomics were done on selected
human tissue and plasma samples. The overall aim was to identify wound
healing and repair mechanisms in aged humans and to define diagnostically
relevant biomarkers which were integrated in targeted, diagnostic microarrays.
 
Further information at RESOLVE Website


2) Cancer Diagnostics:
Serum Autoantibody testing for early diagnosis of breast cancer
Protein chip technology (AIT) and phage-display (BOKU) was used for
identification of auto-antibody-based markers. Therefore serum of patients
with malignant and benign breast tumours and healthy controls were used
(MUW), then a prototype test was developed and validated using 1200 serum
samples. Hence an assay was developed which in addition to mammography
improves the detection and diagnosis of early-stage breast cancer.

Further information at Cancer Diagnostics AIT


3) EurHEALTHAgeing:
EurHEALTHAgeing is an ongoing multidisciplinary project linking studies of

early developmental processes with those on longevity and ageing by
combining use of cutting edge technologies such as post-translational
modifications, DNA methylation, metabolomics and genomics with unique
cohorts with multiple ageing phenotypes. We used four key European study
cohorts with rich early life data and age-related health outcomes. We explored
a unique twin dataset, two birth cohorts with extensive maternal, pre- and perinatal
data and a population based cohort of subjects in their 60s to 70s. By
analysing specific age related metabolomic and epigenetic data (methylation
and post-translational modification) and correlating it to early life events,
genetics and ageing outcomes we provided major insights into developmental
processes that influence longevity and ageing.
This allows us to develop biomarkers of ageing that reflect the role of early
development on ageing, potentially identifying pathways for therapeutic
intervention when the process is still reversible.

Further information at EurHEALTHAgeing

PD Dr. Andreas Weinhäusel

Tel: +43 50550 4455
AIT Austrian Institute of Technology
Muthgasse 11, 1190 Vienna
 

Mag. Dr. Christa Nöhammer

Tel: +43 50550 4404
AIT Austrian Institute of Technology
Muthgasse 11, 1190 Vienna

 

1)    Ion Torrent PGM
 
2)    Access to Ion Proton

3)    LightCycler 480

4)    Biomark Fluidigm

5)    Agilent Scanner & Bioanalyzer

6)    AIT 16k protein- & 170k peptide array

7)    Luminex FlexMap3D